Virax Biolabs Group Limited公布了其候选疗法Viraximmune™在治疗长新冠及相关急性感染后综合征(PAIS)方面获得的积极早期临床数据。初步研究结果显示,该疗法展现出良好的安全性与潜在疗效,为应对这类复杂后遗症带来了新的希望。
Virax Biolabs Group Limited公布了其候选疗法Viraximmune™在治疗长新冠及相关急性感染后综合征(PAIS)方面获得的积极早期临床数据。初步研究结果显示,该疗法展现出良好的安全性与潜在疗效,为应对这类复杂后遗症带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.